acquired generalized lipodystrophy also known lawrence abbreviation agl rare skin condition appears childhood adolescence characterized fat loss affecting large areas body particularly face arms types lipodystrophy based onset areas affected acquired inherited congenital familial generalized partial acquired inherited lipodystrophy present loss adipose tissues absence nutritional deprivation neartotal loss subcutaneous adipose tissue termed generalized lipodystrophy selective loss adipose tissues denoted partial thus name suggests agl neartotal deficiency adipose tissues body developed later life extremely rare disease cases reported three main etiologies agl suspected autoimmune panniculitisassociated onset disease progresses days weeks months even clinical presentations agl similar lipodystrophies including metabolic complications treatments also similar mainly supportive symptomatic alleviation although hiv druginduced lipodystrophy type acquired lipodystrophy origin specific distinct hence usually discussed agl see hivassociated lipodystrophy clinical presentation similar people congenital lipodystrophy difference agl patients born normal fat distribution symptoms develop childhood adolescence years rarely begins years females often affected males ratio hallmark characteristics widespread loss subcutaneous fat ectopic fat deposition leptin deficiency severe metabolic abnormalities insulin subcutaneous fat loss agl patients visible parts body agl mostly affects face extremities may look sunken swollen however degree location severity may vary especially intraabdominal fat loss subcutaneous fat lost affected areas show prominent structures veins muscle panniculitisassociated agl may present erythematous metabolic complications include insulin resistance high metabolic rate uncontrolled lipid levels hypertriglyceridemia low hdl high ldl patients may develop diabetes mellitus secondary insulin resistance case reports revealed lymphoma present patients prevalence known known cause disease however three origins agl generally suspected panniculitisassociated autoimmuneassociated idiopathic triggers may include infections aggravate panniculitis disease state induce autoimmunity overlap panniculitis autoimmune types also another theory suggest agl autoimmune disease panniculitis described autoimmune disease however triggering factors remains underlying genetic factor may associated however neither confirmed previously reported agl associated panniculitis inflammatory nodules subcutaneous fat type agl adipose destruction originates locally infection inflammation site develops generalized agl autoimmune origin responsible agl autoimmune origin stems autoimmune diseases commonly juvenile dermatomyositis autoimmune hepatitis also occurs rheumatoid arthritis systemic lupus erythematosus sjogren although idiopathic agl accounts agl vary origin unclear known preventive measurement reported exact pathophysiologic mechanism mostly unknown however three main origins autoimmune panniculitis idiopathic may different mechanisms normally adipose tissues contain adipocytes store fat energy fasting period release leptin regulate homeostasis energy sensitize insulin agl patients adipose tissues insufficient leads fat deposition nonadipose tissues muscle liver resulting hypertriglyceridemia continuous elevation triglyceride levels contributes metabolic problems including insulin level leptin body proportional amount adipose tissue present agl patients also deficiency leptin contributes excessive eating worsens metabolic patients agl presence antibodies adipocyte diagnosis made comprehensively together visual observation body fat assessment review lab panels consisting glucose lipid patient history caliper measurements skinfold thickness recommended quantify fat loss supportive measurement skinfold thickness less men women anterior thigh suggestive cutoff diagnosis less commonly biphotonic absorptiometry magnetic resonance imaging mri done measurement body forms insulin resistance may assessed differential resistance conventional therapy hyperglycemia hypertriglyceridemia serves indication lipodystrophy specifically diagnosis strongly considered requiring unitsday insulin persistent elevation mgdl triglyceride use leptin levels carefully low leptin levels helpful making diagnosis specific lipodystrophy high leptin levels help excluding possible lipodystrophy wellestablished standardized leptin ranges initial general approach agl patients treat metabolic complications leptinreplacement therapy andor control abnormal levels lipids glucose antidiabetic medications insulin metformin thiazolidinediones used insulinresistance high glucose levels statins fibrates used hyperlipidemia symptoms persist metreleptin prescribed metreleptin myalept recombinant human leptin analog approved fda generalized lipodystrophy adjunct therapy diet treat complication leptin drug option approved generalized lipodystrophyrelated symptoms intended use patients hivrelated lipodystrophy complications partial although recombinant human leptin analog completely natural leptin produced e coli added methionine residues amino works binding human leptin receptor obr activates receptor belongs class cytokine family signals jakstat pathway available mg powder vial subcutaneous injection upon reconstitution needs protected light treatment patients doctors need enrolled certified myalept risk evaluation mitigation strategy rems program people treatment risk developing antimetreleptin antibodies decrease effectiveness metreleptin increased risk clinical study gl patients took metreleptin increased insulin sensitivity indicated decreased fasting glucose level reduced caloric intake well fasting triglyceride plasmapheresis previously option lowering extremely high triglyceride levels preventing pancreatitis painful xanthoma use decreased approval cosmetic treatments facial reconstruction implants done replace adipose tissues lifestyle modifications also recommended including changes less fat diet exercise prognosis disease unknown december many researches treatment lipodystrophy focus safety efficacy leptin replacement therapy outlook positive many studies according prospective openlabel clinical study nih metreleptin decreased fasting glucose level mgdl mgdl total cholesterol mgdl mgdl triglycerides months use patients also decreased use antidiabetic medications lipidlowering medications insulin clinical reports studying patients diagnosed agl accompanied hypoleptinemia uncontrolled diabetes hypertriglyceridemia treated metreleptin weeks patients great reduction normalized serum triglycerides mean decline patients reported improved quality life reduced need medications without significant adverse one research published reported middleaged patient developed agl treatment recovery autoimmune thrombocytopenia included immunoglobulin therapy suggests autoimmune trigger may contribute development agl researches focus genetics lipodystrophy however relevance acquired generalized lipodystrophy confirmed far one clinical report published july stated two brothers juvenileonset generalized lipodystrophy due lamin cspecific mutation unknown point fall acquired familial many published case reports metaanalysis published case reports published within decade helpful establishing patient demographic etiologies prognosis diagnosisopinion